Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXPEDE-1 study of Nexagon for persistent corneal epithelial defects
2023-507030-24-00Phase 2Authorised
- Sponsor
- Glaukos Corporation
- Start
- Apr 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of lufepirsen in corneal persistent epithelial defect (PED) (3 arms), sponsored by Glaukos Corporation. Primary endpoint: Durable corneal re-epithelialization by central reading center. Planned start Apr 2025; status: authorised.
02
Drugs
lufepirsen
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on 2023-507030-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507030-24-00.